BIOMAT Database Logo BIOMAT Database Logo

Phase I toxicity study of methanol-extracted residue of Bacillus Calmette-Guérin by the iv route. 1979

J A Maroun, and J R Quesada, and E M Hersh, and J U Gutterman, and S Richman, and M A Schwarz, and N Parker

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003872 Dermatitis Any inflammation of the skin. Dermatitides
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D005260 Female Females
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias

Related Publications

J A Maroun, and J R Quesada, and E M Hersh, and J U Gutterman, and S Richman, and M A Schwarz, and N Parker
Phase I study of iv administration of methanol extraction residue of Bacillus Calmette-Guérin.
January 1979, Cancer treatment reports,
J A Maroun, and J R Quesada, and E M Hersh, and J U Gutterman, and S Richman, and M A Schwarz, and N Parker
Phase I study of immunotherapy with methanol extraction residue (MER) of bacillus Calmette-Guérin.
January 1977, Cancer treatment reports,
J A Maroun, and J R Quesada, and E M Hersh, and J U Gutterman, and S Richman, and M A Schwarz, and N Parker
Preclinical study of iv administration of the methanol extraction residue of bacillus Calmette-Guérin.
August 1977, Cancer treatment reports,
J A Maroun, and J R Quesada, and E M Hersh, and J U Gutterman, and S Richman, and M A Schwarz, and N Parker
Systemic epithelioid granulomata following immunotherapy with methanol extracted residue of bacillus Calmette-Guérin.
April 1978, Cancer treatment reports,
J A Maroun, and J R Quesada, and E M Hersh, and J U Gutterman, and S Richman, and M A Schwarz, and N Parker
Immunoprophylaxis of methylcholanthrene-induced tumors in mice with Bacillus Calmette-Guérin and methanol-extracted residue.
March 1973, Cancer research,
J A Maroun, and J R Quesada, and E M Hersh, and J U Gutterman, and S Richman, and M A Schwarz, and N Parker
Procarbazine, vinblastine, and actinomycin D in stage III and IV melanoma with or without methanol-extracted residue of Bacillus Calmette-Guérin.
February 1979, Cancer treatment reports,
J A Maroun, and J R Quesada, and E M Hersh, and J U Gutterman, and S Richman, and M A Schwarz, and N Parker
Effects of methanol extraction residue of Bacillus calmette-Guérin in humans.
April 1977, Cancer research,
J A Maroun, and J R Quesada, and E M Hersh, and J U Gutterman, and S Richman, and M A Schwarz, and N Parker
Characterization of methanol extraction residue (MER) from Bacillus Calmette-Guérin (BCG).
October 1979, The Journal of antibiotics,
J A Maroun, and J R Quesada, and E M Hersh, and J U Gutterman, and S Richman, and M A Schwarz, and N Parker
Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
April 1978, Cancer treatment reports,
J A Maroun, and J R Quesada, and E M Hersh, and J U Gutterman, and S Richman, and M A Schwarz, and N Parker
Intravesical and intradermal Bacillus Calmette-Guérin application. A phase I study to the toxicity of a Dutch Bacillus Calmette-Guérin preparation in patients with superficial bladder cancer.
January 1988, European urology,
Copied contents to your clipboard!